As Covid drug cash dwindles, Vigonvita targets new remedies
A Chinese biotech that made a name for itself by co-developing an anti-Covid drug has filed for a stock market listing to fund research into tackling other conditions Key Takeaways:…
Recent Articles
RELATED ARTICLES
-
Junshi narrows its losses but delivers no cure for share price woes
1877.HK 688180.SHG -
Akeso marks profit milestone with swift rights issue
9926.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- InSilico seeks IPO boost to get AI drugs over the line
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
